NCT03315897View on ClinicalTrials.gov

Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

October 1, 2022

Study Completion Date

October 1, 2022

Conditions
Bipolar DisorderCognitive ImpairmentUnipolar Depression
Interventions
DRUG

Erythropoietin

40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 12 times as intravenous infusions over 15 minutes.

DRUG

Saline

1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes

Trial Locations (1)

2100

Mental Health Services, Capital Region of Denmark, Copenhagen University Hospital, Rigshospitalet, Copenhagen

All Listed Sponsors
collaborator

Mental Health Services in the Capital Region, Denmark

OTHER

collaborator

Lundbeck Foundation

OTHER

lead

Lars Vedel Kessing

OTHER

NCT03315897 - Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders | Biotech Hunter | Biotech Hunter